Hepatic Steatosis and Weight Gain During the Coronavirus Disease 2019 Pandemic Among People With Human Immunodeficiency Virus: Impact of Therapy With Tenofovir Alafenamide

Santos, Marta; Corma Gómez, Anaïs; Martin Carmona, Jesica; Perez Garcia, Margarita; Martin Sierra, Carmen; Rincón Mayo, Pilar; González Serna, Alejandro; Pineda, Juan Antonio; Real, Luis Miguel; Macias, Juan

doi:10.1093/ofid/ofad532

Artículo

dc.creator	Santos, Marta	es
dc.creator	Corma Gómez, Anaïs	es
dc.creator	Martin Carmona, Jesica	es
dc.creator	Perez Garcia, Margarita	es
dc.creator	Martin Sierra, Carmen	es
dc.creator	Rincón Mayo, Pilar	es
dc.creator	González Serna, Alejandro	es
dc.creator	Pineda, Juan Antonio	es
dc.creator	Real, Luis Miguel	es
dc.creator	Macias, Juan	es
dc.date.accessioned	2024-04-04T12:13:59Z
dc.date.available	2024-04-04T12:13:59Z
dc.date.issued	2023-10-31
dc.identifier.citation	Santos, M., Corma Gómez, A., Martin Carmona, J., Perez Garcia, M., Martin Sierra, C., Rincón Mayo, P.,...,Macias, J. (2023). Hepatic Steatosis and Weight Gain During the Coronavirus Disease 2019 Pandemic Among People With Human Immunodeficiency Virus: Impact of Therapy With Tenofovir Alafenamide. Open Forum Infectious Diseases, 10 (11), ofad532. https://doi.org/10.1093/ofid/ofad532.
dc.identifier.issn	2328-8957	es
dc.identifier.uri	https://hdl.handle.net/11441/156664
dc.description.abstract	Lockdown due to the coronavirus disease 2019 (COVID-19) pandemic led to increases in weight in part of the population. Weight gain leads to hepatic steatosis (HS). Antiretroviral treatment could also influence HS in people with human immunodeficiency virus (PWH). The impact of lockdown on HS in PWH is unknown. The aim of this study was to analyze the changes in HS, as measured by the controlled attenuation parameter (CAP), during the COVID-19 pandemic in PWH.	es
dc.description.sponsorship	Instituto de Salud Carlos III y Fondos Europeos FEDER PI018/00606	es
dc.format	application/pdf	es
dc.language.iso	eng	es
dc.publisher	Oxford University Press	es
dc.relation.ispartof	Open Forum Infectious Diseases, 10 (11), ofad532.
dc.rights	Attribution-NonCommercial-NoDerivatives 4.0 Internacional	*
dc.rights.uri	http://creativecommons.org/licenses/by-nc-nd/4.0/	*
dc.subject	HIV infection	es
dc.subject	liver fibrosis	es
dc.subject	SARS-CoV-2	es
dc.subject	steatosis	es
dc.subject	TAF	es
dc.title	Hepatic Steatosis and Weight Gain During the Coronavirus Disease 2019 Pandemic Among People With Human Immunodeficiency Virus: Impact of Therapy With Tenofovir Alafenamide	es
dc.type	info:eu-repo/semantics/article	es
dc.type.version	info:eu-repo/semantics/publishedVersion	es
dc.rights.accessRights	info:eu-repo/semantics/openAccess	es
dc.contributor.affiliation	Universidad de Sevilla. Departamento de Fisiología	es
dc.relation.projectID	PI018/00606	es
dc.relation.publisherversion	https://doi.org/10.1093/ofid/ofad532	es
dc.identifier.doi	10.1093/ofid/ofad532	es
dc.journaltitle	Open Forum Infectious Diseases	es
dc.publication.volumen	10	es
dc.publication.issue	11	es
dc.publication.initialPage	ofad532	es
dc.contributor.funder	Instituto de Salud Carlos III	es
dc.contributor.funder	Fondos Europeos FEDER	es

Ficheros	Tamaño	Formato	Ver	Descripción
ofad532.pdf	557.8Kb	[PDF]	Ver/Abrir

Este registro aparece en las siguientes colecciones

Artículos (Fisiología)

Mostrar el registro sencillo del ítem

Excepto si se señala otra cosa, la licencia del ítem se describe como: Attribution-NonCommercial-NoDerivatives 4.0 Internacional